Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BUCiL: Re-introduction of Cisplatin-Pemetrexed-Bevacizumab in NSCLC
NCT01705184Phase 2Completed
- Sponsor
- IFCT
- Start
- Dec 2012
- Primary completion
- Jan 2016
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Cisplatin micelle injection (HA132), pemetrexed, bevacizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by IFCT. Started Dec 2012; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)pemetrexedbevacizumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT01705184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01705184.